{
    "clinical_study": {
        "@rank": "9752", 
        "arm_group": [
            {
                "arm_group_label": "NESP 60\u03bcg", 
                "arm_group_type": "Active Comparator", 
                "description": "Prefilled syringe filled with Darbepoetin alfa 60\u03bcg"
            }, 
            {
                "arm_group_label": "CKD-11101 60\u03bcg", 
                "arm_group_type": "Experimental", 
                "description": "Prefilled syringe filled with Darbepoetin alfa 60\u03bcg"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the pharmacokinetics of CKD-11101 and NESP after\n      IV administration in health male volunteers"
        }, 
        "brief_title": "Pharmacokinetics Study of CKD-11101 and NESP After IV Administration in Health Male Volunteers", 
        "condition": "Anemia", 
        "condition_browse": {
            "mesh_term": "Anemia"
        }, 
        "detailed_description": {
            "textblock": "Healthy volunteers are administrated CKD-11101 60\u03bcg and NESP 60\u03bcg once intravenously.\n      (crossover) Every time before and after taking each medication, PK parameters and safety of\n      CKD-11101 60\u03bcg and NESP 60\u03bcg are performed using a blood sample and conducting some\n      tests(Laboratory test, V/S and Physical Examination, etc) respectively."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed the informed consent form prior to study participation.\n\n          -  A healthy male volunteer between 20 and 55 years old.\n\n          -  Body weight between 55kg and 90kg, BMI between 18 and 27.\n\n          -  Appropriate subject for the study judging from investigator(physical examination,\n             laboratory test, interview, etc.)\n\n        Exclusion Criteria:\n\n          -  Have the medical history of allergic diseases including hypersensitivity against drug\n             or clinically significant allergic diseases\n\n          -  Clinically significant hepatic, renal, respiratory system, endocrine system, nervous\n             system, immune system, hematologic, psychiatric, circulatory system, tumor or have\n             history of tumor\n\n          -  Have abnormal laboratory result.\n\n               -  Hemoglobin < 12g/dL or > 17g/dL\n\n               -  Vitamin B12 < 200pg/mL\n\n               -  Ferritin < 21.8ng/mL\n\n               -  Transferrin < 190mg/dL\n\n               -  Reticulocyte over the normal limit\n\n               -  Positive for the Triage TOX drug on urine (cocaine, amphetamines, barbiturates,\n                  opiates, benzodiazepine, cannabinoids)\n\n               -  Positive for HIV antibody, HBsAg, HCV antibody test\n\n          -  A heavy smoker (cigarette > 10 cigarettes per day)\n\n          -  Administer EPO, darbepoetin, immunoglobulin or IV iron within 3 months prior to the\n             first IP administration\n\n          -  Have hypersensitivity reactions history for EPO, darbepoetin, excipient of IP or iron\n             tablets\n\n          -  sit SBP < 90mmHg or sit SBP > 140mmHg or sit DBP < 55mmHg or sit DBP > 90mmHg or\n             Pulse rate > 100 per/min\n\n          -  History of hemoglobinopathy or inflammatory disease or drug abuse within 6 months\n             before screening\n\n          -  Subject takes ethical drug or herbal medicine within 14 days,  OTC or vitamin\n             supplements within 7 days before the first IP administration\n\n          -  Participated in the other clinical trials and administrated IP within 8 weeks prior\n             to the first IP administration\n\n          -  A heavy alcohol consumer (alcohol > 21 units/week) or cannot stop drinking\n\n          -  Bleed or donate blood (> 400mL) within 8 weeks before the first IP administration\n\n          -  Participated in this clinical trials and administrated IP\n\n          -  Have a diet within 2 days before the first IP administration or cannot stop having\n\n               -  food containing grapefruit\n\n               -  food containing caffeine\n\n          -  Disagree to avoid getting pregnant during clinical trial\n\n          -  An impossible one who participates in clinical trial by investigator's decision\n             including laboratory test result, other reason"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "31", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "September 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01684605", 
            "org_study_id": "136HPS12D"
        }, 
        "intervention": [
            {
                "arm_group_label": "NESP 60\u03bcg", 
                "description": "Administrated NESP 60\u03bcg once intravenously", 
                "intervention_name": "NESP 60\u03bcg", 
                "intervention_type": "Drug", 
                "other_name": "NESP 60\u03bcg"
            }, 
            {
                "arm_group_label": "CKD-11101 60\u03bcg", 
                "description": "Administrated CKD-11101 60\u03bcg once intravenously", 
                "intervention_name": "CKD-11101 60\u03bcg", 
                "intervention_type": "Drug", 
                "other_name": "CKD-11101 60\u03bcg"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Darbepoetin alfa"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "CKD-11101", 
            "NESP", 
            "Darbepoetin alfa", 
            "Anemia", 
            "intravenous", 
            "Pharmacokinetics", 
            "Phase 1"
        ], 
        "lastchanged_date": "March 14, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Seoul national university hospital"
            }
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Active Control, Single Dosing, Crossover Clinical Trial to Investigate the Pharmacokinetics of CKD-11101 and NESP After IV Administration in Health Male Volunteers", 
        "overall_official": {
            "affiliation": "Seoul National University Hospital", 
            "last_name": "Kyung Sang Yu, Ph.D", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "January 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Assess AUClast of darbepoetin alfa", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.25h, 0.5h, 0.75h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 168h, 264h"
            }, 
            {
                "measure": "Assess Cmax of darbepoetin alfa", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.25h, 0.5h, 0.75h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 168h, 264h"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01684605"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Assess AUCinf of darbepoetin alfa", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.25h, 0.5h, 0.75h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 168h, 264h"
            }, 
            {
                "measure": "Assess Tmax of darbepoetin alfa", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.25h, 0.5h, 0.75h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 168h, 264h"
            }, 
            {
                "measure": "Assess t1/2 of darbepoetin alfa", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.25h, 0.5h, 0.75h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 168h, 264h"
            }, 
            {
                "measure": "Assess CL of darbepoetin alfa", 
                "safety_issue": "No", 
                "time_frame": "Pre-dose, 0.25h, 0.5h, 0.75h, 1h, 2h, 3h, 4h, 6h, 8h, 12h, 24h, 36h, 48h, 72h, 96h, 120h, 168h, 264h"
            }
        ], 
        "source": "Chong Kun Dang Pharmaceutical", 
        "sponsors": {
            "collaborator": {
                "agency": "Seoul National University Hospital", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Chong Kun Dang Pharmaceutical", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics/Dynamics Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2013"
    }
}